https://mb.cision.com/Public/18595/3794280/96cf8050614df072_800x800ar.png
** UCB Provides Update on U.S. FDA Review of the Biologics License Applicat=
ion for Bimekizumab
------------------------------------------------------------
Brussels (Belgium), 26th June 2023 =E2=80=93 18:30 CEST =E2=80=93 Regulated=
Information =E2=80=93 Inside Information =E2=80=93 UCB, a global biopharma=
ceutical company, today announced that the Biologics License Application (B=
LA) for bimekizumab for the treatment of adults with moderate to severe pla=
que psoriasis remains under review with the U.S. Food & Drug Administration=
(FDA). UCB previously communicated (https://www.ucb.com/stories-media/Pres=
s-Releases/article/UCB-Announces-FDA-Acceptance-of-BLA-Resubmission-for-Bim=
ekizumab) the FDA action was expected in Q2, 2023. UCB now anticipates the =
FDA action in Q3, 2023. There are no open Information Requests from the FDA=
regarding the BLA for bimekizumab.
UCB is committed to ongoing collaboration with the FDA in order to bring bi=
mekizumab to people in the U.S. living with moderate to severe plaque psori=
asis as soon as possible.=C2=A0
Bimekizumab, an IL-17A and IL-17F inhibitor, is currently approved for mode=
rate to severe psoriasis by 10 regulatory authorities and in 39 countries w=
orldwide.^1-8 In June 2023, in countries of the European Union/European Eco=
nomic Area, bimekizumab was approved for two additional indications =E2=80=
=93 the treatment of adults with active psoriatic arthritis, and for the tr=
eatment of adults with active axial spondyloarthritis (axSpA), including no=
n-radiographic axSpA and ankylosing spondylitis, also known as radiographic=
axSpA.^2
UCB confirms its previously communicated 2023 financial guidance range.
UCB will host a UCB Investor Call on 27th June: 15:15=E2=80=9315:45 CEST; 0=
9:15 am =E2=80=9309:45 am EST; 14:15=E2=80=9314:45 BST.=C2=A0Participant In=
ternational Dial In: +1-412-902-6510; Participant UK/EU Dial In: +44 203 51=
43188.
Notes to editors:
About bimekizumab
Bimekizumab is a humanized monoclonal IgG1 antibody that is designed to sel=
ectively inhibit both interleukin 17A (IL-17A) and interleukin 17F (IL-17F)=
, two key cytokines driving inflammatory processes.^1 In August 2021, bimek=
izumab=E2=96=BCreceived marketing authorization in countries of the Europea=
n Union (EU)/European Economic Area (EEA) and Great Britain, for the treatm=
ent of moderate to severe plaque psoriasis in adults who are candidates for=
systemic therapy.^2,3=C2=A0In January 2022, bimekizumab received marketing=
authorization in Japan for the treatment of plaque psoriasis, generalized =
pustular psoriasis and psoriatic erythroderma in patients who are not suffi=
ciently responding to existing treatments.^4 In February 2022, March 2022 a=
nd April 2023, bimekizumab received marketing authorization in Canada, Aust=
ralia and Mexico, respectively, for the treatment of moderate to severe pla=
que psoriasis in adults who are candidates for systemic therapy or photothe=
rapy.^5,6=C2=A0In July 2022, October 2022, January 2023 and May 2023 bimeki=
zumab was approved in Saudi Arabia^7, Switzerland^8, the United Arab Emirat=
es and Kuwait, respectively, for the treatment of moderate to severe plaque=
psoriasis in adults who are candidates for systemic therapy.=C2=A0
In June 2023, bimekizumab was approved in countries of the EU/EEA, alone or=
in combination with methotrexate for the treatment of active psoriatic art=
hritis in adults who have had an inadequate response or who have been intol=
erant to one or more disease-modifying antirheumatic drugs.^2 In June 2023,=
bimekizumab was approved in countries of the EU/EEA, for the treatment of =
adults with active non-radiographic axial spondyloarthritis with objective =
signs of inflammation as indicated by elevated C-reactive protein and/or ma=
gnetic resonance imaging who have responded inadequately or are intolerant =
to non-steroidal anti-inflammatory drugs, and for the treatment of adults w=
ith active ankylosing spondylitis who have responded inadequately or are in=
tolerant to conventional therapy.^2=C2=A0
=E2=96=BC This medicinal product is subject to additional monitoring. This =
will allow quick identification of new safety information. Healthcare profe=
ssionals are asked to report any suspected adverse reactions.
For further information, contact UCB:=C2=A0
Investor Relations
Antje Witte
T +32.2.559.94.14=C2=A0
email antje.witte@ucb.com=C2=A0
Corporate Communications
Laurent Schots=C2=A0
T +32.2.559.92.64=C2=A0
email laurent.schots@ucb.com
Brand Communications
Eimear O=E2=80=99Brien
T +32.2.559.92.71
email eimear.obrien@ucb.com=C2=A0
About UCB=C2=A0
UCB, Brussels, Belgium (www.ucb.com) is a global biopharmaceutical company =
focused on the discovery and development of innovative medicines and soluti=
ons to transform the lives of people living with severe diseases of the imm=
une system or of the central nervous system. With approximately 8,700 peopl=
e in approximately 40 countries, the company generated revenue of =E2=82=AC=
5.5 billion in 2022. UCB is listed on Euronext Brussels (symbol: UCB). Foll=
ow us on Twitter: @UCB_news.
Forward looking statements=C2=A0
This press release may contain forward-looking statements including, withou=
t limitation, statements containing the words =E2=80=9Cbelieves=E2=80=9D, =
=E2=80=9Canticipates=E2=80=9D, =E2=80=9Cexpects=E2=80=9D, =E2=80=9Cintends=
=E2=80=9D, =E2=80=9Cplans=E2=80=9D, =E2=80=9Cseeks=E2=80=9D, =E2=80=9Cestim=
ates=E2=80=9D, =E2=80=9Cmay=E2=80=9D, =E2=80=9Cwill=E2=80=9D, =E2=80=9Ccont=
inue=E2=80=9D and similar expressions. These forward-looking statements are=
based on current plans, estimates and beliefs of management. All statement=
s, other than statements of historical facts, are statements that could be =
deemed forward-looking statements, including estimates of revenues, operati=
ng margins, capital expenditures, cash, other financial information, expect=
ed legal, arbitration, political, regulatory or clinical results or practic=
es and other such estimates and results. By their nature, such forward-look=
ing statements are not guarantees of future performance and are subject to =
known and unknown risks, uncertainties and assumptions which might cause th=
e actual results, financial condition, performance or achievements of UCB, =
or industry results, to differ materially from those that may be expressed =
or implied by such forward-looking statements contained in this press relea=
se. Important factors that could result in such differences include: change=
s in general economic, business and competitive conditions, the inability t=
o obtain necessary regulatory approvals or to obtain them on acceptable ter=
ms or within expected timing, costs associated with research and developmen=
t, changes in the prospects for products in the pipeline or under developme=
nt by UCB, effects of future judicial decisions or governmental investigati=
ons, safety, quality, data integrity or manufacturing issues; potential or =
actual data security and data privacy breaches, or disruptions of our infor=
mation technology systems, product liability claims, challenges to patent p=
rotection for products or product candidates, competition from other produc=
ts including biosimilars, changes in laws or regulations, exchange rate flu=
ctuations, changes or uncertainties in tax laws or the administration of su=
ch laws, and hiring and retention of its employees. There is no guarantee t=
hat new product candidates will be discovered or identified in the pipeline=
, will progress to product approval or that new indications for existing pr=
oducts will be developed and approved. Movement from concept to commercial =
product is uncertain; preclinical results do not guarantee safety and effic=
acy of product candidates in humans. So far, the complexity of the human bo=
dy cannot be reproduced in computer models, cell culture systems or animal =
models. The length of the timing to complete clinical trials and to get reg=
ulatory approval for product marketing has varied in the past and UCB expec=
ts similar unpredictability going forward. Products or potential products, =
which are the subject of partnerships, joint ventures or licensing collabor=
ations may be subject to differences disputes between the partners or may p=
rove to be not as safe, effective or commercially successful as UCB may hav=
e believed at the start of such partnership. UCB=E2=80=99s efforts to acqui=
re other products or companies and to integrate the operations of such acqu=
ired companies may not be as successful as UCB may have believed at the mom=
ent of acquisition. Also, UCB or others could discover safety, side effects=
or manufacturing problems with its products and/or devices after they are =
marketed. The discovery of significant problems with a product similar to o=
ne of UCB=E2=80=99s products that implicate an entire class of products may=
have a material adverse effect on sales of the entire class of affected pr=
oducts. Moreover, sales may be impacted by international and domestic trend=
s toward managed care and health care cost containment, including pricing p=
ressure, political and public scrutiny, customer and prescriber patterns or=
practices, and the reimbursement policies imposed by third-party payers as=
well as legislation affecting biopharmaceutical pricing and reimbursement =
activities and outcomes. Finally, a breakdown, cyberattack or information s=
ecurity breach could compromise the confidentiality, integrity and availabi=
lity of UCB=E2=80=99s data and systems.=C2=A0
Given these uncertainties, you should not place undue reliance on any of su=
ch forward-looking statements. There can be no guarantee that the investiga=
tional or approved products described in this press release will be submitt=
ed or approved for sale or for any additional indications or labelling in a=
ny market, or at any particular time, nor can there be any guarantee that s=
uch products will be or will continue to be commercially successful in the =
future.
UCB is providing this information, including forward-looking statements, on=
ly as of the date of this press release. UCB expressly disclaims any duty t=
o update any information contained in this press release, either to confirm=
the actual results or to report or reflect any change in its forward-looki=
ng statements with regard thereto or any change in events, conditions or ci=
rcumstances on which any such statement is based, unless such statement is =
required pursuant to applicable laws and regulations.=C2=A0
Additionally, information contained in this document shall not constitute a=
n offer to sell or the solicitation of an offer to buy any securities, nor =
shall there be any offer, solicitation or sale of securities in any jurisdi=
ction in which such offer, solicitation or sale would be unlawful prior to =
the registration or qualification under the securities laws of such jurisdi=
ction.=C2=A0
References
1. Glatt S, Helmer E, Haier B, et al. First-in-human randomized study of bi=
mekizumab, a humanized monoclonal antibody and selective dual inhibitor of =
IL-17A and IL-17F, in mild psoriasis. Br J Clin Pharmacol. 2017;83(5):991=
=E2=80=931001.
2. BIMZELX (bimekizumab) EU SmPC. https://www.ema.europa.eu/en/documents/pr=
oduct-information/bimzelx-epar-product-information_en.pdf =C2=A0Accessed: J=
une 2023.
3. BIMZELX (bimekizumab) GB SmPC. https://www.medicines.org.uk/emc/product/=
12834; https://www.medicines.org.uk/emc/product/12833 Accessed: June 2023.
4. Pharmaceuticals and Medical Devices Agency. https://www.pmda.go.jp/engli=
sh/review-services/reviews/approved-information/drugs/0001.html. Accessed: =
June 2023.
5. BIMZELX (bimekizumab) Canada Product Monograph. Available at: https://pd=
f.hres.ca/dpd_pm/00064702.PDF. Accessed: June 2023.
6. BIMZELX. Australian Prescription Medicine Decision Summaries. Available =
at: https://www.tga.gov.au/apm-summary/bimzelx. Accessed: June 2023.
7. Saudi Food & Drug Authority. https://www.sfda.gov.sa/sites/default/files=
/2023-04/Bimzelx.pdf. Last accessed: June 2023.
8. Swissmedic. Available at: https://www.swissmedic.ch/swissmedic/en/home/a=
bout-us/publications/public-summary-swiss-par/public-summary-swiss-par-bimz=
elx.html (https://www.swissmedic.ch/swissmedic/en/home/about-us/publication=
s/public-summary-swiss-par/public-summary-swiss-par-bimzelx.html.) . =C2=A0=
Last accessed: June 2023. =C2=A0
GenericFile
UCB PR BKZ Update June 26 2023 ENG (https://mb.cision.com/Public/18595/3794=
280/9cbc83d1d00af9c5.pdf)
______________________
If you would rather not receive future communications from UCB SA, please g=
o to https://eu.vocuspr.com/OptOut.aspx?2973226x20421x139338x1x6868579x2400=
0x6&Email=3Dregnews%40symexglobal.com.
UCB SA, All=C3=A9e de la Recherche, 60 ., Brussels, . B - 1070 Belgium
26/04/2024 20:00
25/04/2024 18:00
25/04/2024 07:01
23/04/2024 20:00
22/04/2024 07:01
19/04/2024 20:00
17/04/2024 07:01
12/04/2024 20:00
12/04/2024 18:01
12/04/2024 07:01